Developing novel antibodies of the IgE class to target solid tumours. Supporting the first-in-class, first-in-man, Phase 1 clinical trial of MOv18 IgE (ClinicalTrials.gov Identifier: NCT02546921). Now funded by IGEM Therapeutics Ltd (www.igemtherapeutics.com). Research programs include pre-clinical development of IgE antibodies against ovarian, breast (including TNBC), melanoma and lung cancers.